TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting | Zendy

George Fountzilas | Zendy; Eleni Giannoulatou | Zendy; Zoi Alexopoulou | Zendy; Flora Zagouri | Zendy; Eleni Timotheadou | Zendy; Kyriaki Papadopoulou | Zendy; Sotiris Lakis | Zendy; Mattheos Bobos | Zendy; Christos Poulios | Zendy; Maria Sotiropoulou | Zendy; Aggeliki Lyberopoulou | Zendy; Helen Gogas | Zendy; George Pentheroudakis | Zendy; Dimitrios Pectasides | Zendy; Angelos Koutras | Zendy; Christos Christodoulou | Zendy; Christos N. Papandreou | Zendy; Epamitas Samantas | Zendy; Pavlos Papakostas | Zendy; P. Kosmidis | Zendy; Dimitrios Bafaloukos | Zendy; Charisios Karanikiotis | Zendy; Meletios Α. Dimopoulos | Zendy; Vassiliki Kotoula | Zendy

Open Access

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

Author(s) -

George Fountzilas,

Eleni Giannoulatou,

Zoi Alexopoulou,

Flora Zagouri,

Eleni Timotheadou,

Kyriaki Papadopoulou,

Sotiris Lakis,

Mattheos Bobos,

Christos Poulios,

Maria Sotiropoulou,

Aggeliki Lyberopoulou,

Helen Gogas,

George Pentheroudakis,

Dimitrios Pectasides,

Angelos Koutras,

Christos Christodoulou,

Christos N. Papandreou,

Epamitas Samantas,

Pavlos Papakostas,

P. Kosmidis,

Dimitrios Bafaloukos,

Charisios Karanikiotis,

Meletios Α. Dimopoulos,

Vassiliki Kotoula

Publication year - 2016

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.9022

Subject(s) - trastuzumab , medicine , immunohistochemistry , oncology , anthracycline , breast cancer , taxane , mutation , adjuvant , cancer , chemotherapy , cancer research , gene , biology , genetics

We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- and post-trastuzumab era.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research